Is Quoin Pharmaceuticals, Ltd. (QNRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 100.3% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 100.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 89.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 100.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 89.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -651.4% | |
| Return on Assets (ROA) | -99.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Debt-to-Equity | 17.7 |
| Current Ratio | 1.0 |
| Total Assets | $16M |
Price & Trading
| Last Close | $7.57 |
| 50-Day MA | $8.49 |
| 200-Day MA | $10.12 |
| Avg Volume | 29K |
| Beta | 1.8 |
|
52-Week Range
$5.01
| |
About Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Quoin Pharmaceuticals, Ltd. (QNRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Quoin Pharmaceuticals, Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Quoin Pharmaceuticals, Ltd.'s debt ratio?
Quoin Pharmaceuticals, Ltd.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Quoin Pharmaceuticals, Ltd.'s key financial metrics?
Quoin Pharmaceuticals, Ltd. has a market capitalization of $10M. Return on equity stands at -651.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.